GenSight Biologics S.A.
GenSight Biologics S.A.
Your view on GSGTF
Overview
What the company does, where it operates, and who runs it.
About GenSight Biologics S.A.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laurence Rodriguez
- Headquarters
- 74, rue du Faubourg Saint-Antoine, Paris, FR
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Laurence Rodriguez
- Headquarters
- 74, rue du Faubourg Saint-Antoine, Paris, FR
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.
Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for GenSight Biologics S.A., and the rating behind it. GSGTF last traded at $0.19; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for GenSight Biologics S.A.. Starting points for GenSight Biologics S.A.: EPS -$0.06, beta 0.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for GenSight Biologics S.A.. GenSight Biologics S.A. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for GenSight Biologics S.A.. Trailing twelve-month EPS for GenSight Biologics S.A. stands at -$0.06. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for GenSight Biologics S.A.. GenSight Biologics S.A. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
GenSight Biologics S.A. valued side by side against its closest peers. GenSight Biologics S.A. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold GenSight Biologics S.A., and how their positions are changing. At a $36.1M market value, institutional positions materially move GenSight Biologics S.A.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by GenSight Biologics S.A. executives and directors. Shares of GenSight Biologics S.A. have traded between $0.19 and $0.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming GenSight Biologics S.A.. GenSight Biologics S.A. is a $36.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming GenSight Biologics S.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for GenSight Biologics S.A.. Coverage tracks GenSight Biologics S.A. within Biotechnology (Healthcare). Press releases and market coverage, newest first.